Narrow search
Showing 1 - 10 of 1,459
Cover Image
Evaluation and Learning in R&D Investment
Frankel, Alex; Krieger, Joshua L.; Li, Danielle; … - National Bureau of Economic Research - 2023
We examine the role of spillover learning in shaping the value of exploratory versus incremental R&D. Using data from drug development, we show that novel drug candidates generate more knowledge spillovers than incremental ones. Despite being less likely to reach regulatory approval, they are...
Persistent link: https://www.econbiz.de/10014287391
Cover Image
Improving Regulation for Innovation : Evidence from China's Pharmaceutical Industry
Jia, Ruixue; Ma, Xiao; Yang, Jianan; Zhang, Yiran - National Bureau of Economic Research - 2023
This study investigates how enhanced regulation can promote innovation, focusing on the impacts of a significant … recognized the improvement in drug innovation, as reflected in stock price adjustments post new drug registrations after the … latecomers could boost their innovation potential by adopting specific, effective regulatory practices from frontier countries …
Persistent link: https://www.econbiz.de/10014447297
Cover Image
Calculating the Costs and Benefits of Advance Preparations for Future Pandemics
Glennerster, Rachel; Snyder, Christopher M.; Tan, … - National Bureau of Economic Research - 2022
The Covid-19 pandemic is estimated to have caused over 7 million deaths and reduced economic output by over $13 trillion to date. While vaccines were developed and deployed with unprecedented speed, pre-pandemic investments could have accelerated their widespread introduction, saving millions of...
Persistent link: https://www.econbiz.de/10013435127
Cover Image
An Optimal Mechanism to Fund the Development of Vaccines Against Emerging Epidemics
Snyder, Christopher M.; Hoyt, Kendall; Gouglas, Dimitrios - National Bureau of Economic Research - 2022
We derive the optimal funding mechanism to incentivize development and production of vaccines against diseases with epidemic potential. In the model, suppliers' costs are private information and investments are noncontractible, precluding cost-reimbursement contracts, requiring fixed-price...
Persistent link: https://www.econbiz.de/10013462668
Cover Image
'We Are Not Guinea Pigs' : The Effects of Disclosure of Medical Misconduct on Vaccine Compliance
Archibong, Belinda; Annan, Francis - National Bureau of Economic Research - 2023
In 1996, following an epidemic, Pfizer tested a new drug on 200 children in Muslim Nigeria. 11 children died while others were disabled. We study the effects of the disclosure, in 2000, of the deaths of Muslim children in the Pfizer trials on vaccine compliance among Muslim mothers. Muslim...
Persistent link: https://www.econbiz.de/10014372412
Cover Image
Evaluating Pharmaceutical Policy Options
Ho, Katherine; Pakes, Ariel - National Bureau of Economic Research - 2024
Our calculations indicate that currently proposed U.S. policies to reduce pharmaceutical prices, though particularly beneficial for low-income and elderly populations, could dramatically reduce firms' investment in highly welfare-improving R&D. The U.S. subsidizes the worldwide pharmaceutical...
Persistent link: https://www.econbiz.de/10014576635
Cover Image
Bargaining and International Reference Pricing in the Pharmaceutical Industry
Dubois, Pierre; Gandhi, Ashvin; Vasserman, Shoshana - National Bureau of Economic Research - 2022
The United States spends twice as much per person on pharmaceuticals as European countries, in large part because prices are much higher in the US. This fact has led policymakers to consider legislation for price controls. This paper assesses the effects of a US international reference pricing...
Persistent link: https://www.econbiz.de/10013210081
Cover Image
Pharmaceutical Innovation, Mortality Reduction, and Economic Growth
Lichtenberg, Frank R. - 1998
We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …
Persistent link: https://www.econbiz.de/10012472240
Cover Image
The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011
Lichtenberg, Frank R. - 2015
of decline across cancer sites. I analyze the effect that pharmaceutical innovation had on premature cancer mortality in … Canada during the period 2000-2011, by investigating whether the cancer sites that experienced more pharmaceutical innovation …The estimates imply that pharmaceutical innovation during the period 1985-1996 reduced the number of years of potential …
Persistent link: https://www.econbiz.de/10012457428
Cover Image
The NBER Orange Book Dataset : A User's Guide
Durvasula, Maya; Hemphill, C. Scott; Ouellette, Lisa … - National Bureau of Economic Research - 2022
This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....
Persistent link: https://www.econbiz.de/10013462677